Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Update

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 3,548 shares, an increase of 31.0% from the January 29th total of 2,708 shares. Based on an average daily volume of 6,498 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the shares of the company are short sold. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 6,498 shares, the short-interest ratio is currently 0.5 days.

Fidelity Disruptive Medicine ETF Stock Down 0.8%

Shares of NASDAQ FMED traded down $0.20 during mid-day trading on Monday, reaching $26.01. 4,027 shares of the company were exchanged, compared to its average volume of 7,313. The stock has a market capitalization of $59.82 million, a P/E ratio of 41.33 and a beta of 1.00. The company’s 50-day simple moving average is $26.85 and its 200-day simple moving average is $26.32. Fidelity Disruptive Medicine ETF has a twelve month low of $20.69 and a twelve month high of $29.07.

Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF

A number of large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Fidelity Disruptive Medicine ETF in the 4th quarter valued at $228,000. Jane Street Group LLC lifted its holdings in shares of Fidelity Disruptive Medicine ETF by 95.4% during the fourth quarter. Jane Street Group LLC now owns 91,414 shares of the company’s stock worth $2,473,000 after buying an additional 44,630 shares in the last quarter. Vise Technologies Inc. bought a new stake in shares of Fidelity Disruptive Medicine ETF in the fourth quarter valued at about $234,000. Glass Jacobson Investment Advisors llc grew its stake in shares of Fidelity Disruptive Medicine ETF by 44.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock valued at $34,000 after acquiring an additional 385 shares in the last quarter. Finally, BXM Wealth LLC acquired a new position in shares of Fidelity Disruptive Medicine ETF during the 4th quarter worth approximately $243,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.